Via Transportation Inc
Technology
Via Transportation Inc (VIA) Stock News
The latest VIA headlines and market coverage — 8 recent stories, updated throughout the day.
- Benzinga·
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Via Transportation, Inc. (VIA) Shareholders to Inquire About Securities Fraud Class Action
A securities fraud class action lawsuit has been filed against Via Transportation, Inc. following its September 2025 IPO at $46 per share. The company failed to disclose declining Annual Run-Rate Revenue per customer and regulatory headwinds in Germany, leading to significant stock price declines. Via's stock has fallen nearly 70% from its IPO price to $14.12 as of May 2026. Shareholders have until August 10, 2026 to file a lead plaintiff motion.
- Benzinga·
VIA Investors Have Opportunity to Lead Via Transportation, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has filed a class action lawsuit against Via Transportation, Inc. (NYSE: VIA) for securities fraud. The company allegedly made false and misleading statements about its business growth and financial performance during its September 2025 IPO. Via claimed durable revenue growth through its 'land and expand' strategy but was actually experiencing declining Annual Run-Rate Revenue (ARR) and growth obstacles. The company only disclosed regulatory pressures in Germany on May 12, 2026, causing investor losses. Investors who purchased securities during the IPO are encouraged to join the lawsuit before August 10, 2026.
- GlobeNewswire Inc.·
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Via Transportation, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VIA
Rosen Law Firm has filed a class action lawsuit against Via Transportation, Inc. (NYSE: VIA) on behalf of IPO investors, alleging that offering documents were false and misleading. The complaint claims Via omitted material facts about declining Platform Annual Run-Rate Revenue and inability to grow in Germany. Via's stock has declined approximately 70% from its IPO price to $14.52, and investors are encouraged to join the class action before the August 10, 2026 deadline to serve as lead plaintiff.
- GlobeNewswire Inc.·
VIA TRANSPORTATION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Via Transportation, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Via Transportation, Inc. alleging that its September 2025 IPO offering documents were false and misleading. The complaint claims Via omitted information about declining growth and inability to expand in Germany. Following a March 2026 report questioning Via's business model, the stock fell 59.7% from its $46 IPO price to $18.51. Investors have until August 10, 2026 to apply as lead plaintiff.
- Benzinga·
Law Offices of Frank R. Cruz Encourages Via Transportation, Inc. (VIA) Shareholders To Inquire About Securities Fraud Class Action
A class action lawsuit has been filed against Via Transportation, Inc. on behalf of shareholders who purchased stock in its September 2025 IPO at $46 per share. The company allegedly made materially false statements and failed to disclose that Annual Run-Rate Revenue per customer was declining and that regulatory issues in Germany would hinder its expansion strategy. Via's stock has fallen nearly 70% from the IPO price to $14.12 per share as of May 2026. Investors have until August 10, 2026 to file a lead plaintiff motion.
- GlobeNewswire Inc.·
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
DBV Technologies announced the first participant screening in the THRIVE phase 2 clinical trial evaluating the efficacy and safety of VIASKIN® Peanut patch in infants aged 6-12 months with peanut allergies. The study aims to enable ad libitum peanut consumption through early intervention immunotherapy, building on positive results from earlier trials in older children.
- GlobeNewswire Inc.·
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
DBV Technologies announced the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in infants ages 6-12 months with peanut allergy. The study will assess whether the patch can enable ad lib (unrestricted) peanut consumption through epicutaneous immunotherapy (EPIT), building on positive results from earlier trials in older age groups.
- GlobeNewswire Inc.·
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
OPTAVIA released research findings showing that clients using their Optimal Weight 5 & 1 Plan with coach support lost up to 10 times more weight and 17 times more fat compared to self-directed participants. The study highlights the importance of human coaching in weight management programs, with research indicating that higher retention rates directly correlate with better weight loss outcomes. OPTAVIA coaches complete a certification program and provide accountability and emotional support rather than clinical guidance.